A collection of 17 conference guides related to AI drug discovery that need attention in 2019

Drug discovery is the beginning of new drug development process Modern drug discovery technology can be divided into three stages: target discovery and confirmation, leader discovery and leader optimization With the discovery and utilization of more and more compounds that can be used for medicine, it is more and more difficult to develop new compounds At the same time, the number of scientific achievements increases in geometric progression, and it is impossible for human beings to fully understand and mine the value of these data Artificial intelligence can get the information of molecular structure from a large number of papers, and can learn independently, establish the relationship among them, and provide new ideas and ideas At present, the introduction of artificial intelligence has begun to reconstruct the process of new drug research and development, and its application in new drug research and development has begun to expand from target selection to more aspects Specifically, the application of artificial intelligence in new drug research and development mainly includes seven directions: target screening, drug screening, drug optimization, patient identification and recruitment, medication compliance management, patient data collection and small molecule drug crystal prediction, covering two stages of new drug discovery and clinical trials Multinational pharmaceutical companies have begun to layout "Ai + new drug research and development" In June 2017, numerate and Takeda pharmaceutical officially signed a contract to cooperate on using numerate's artificial intelligence (AI) technology to find small molecule drugs for oncology, Gastroenterology and central nervous system diseases In July of the same year, GSK entered into cooperation with exscientia The deal involved about $43 million After the cooperation, exscientia will use its AI drug development platform to develop 10 innovative small molecule drug disease targets for GSK In addition, other pharmaceutical giants, including Merck & Co, Johnson & Johnson and Sanofi, are exploring the potential of artificial intelligence to help streamline drug development At the beginning of 2019, new artery medicine compiled and updated the attendance guide of the global conference on artificial intelligence in drug discovery officially released in 2019 (www.dka Global) The purpose of compiling the guide is to make it easier for pharmaceutical companies, investors, scientists and interested public to understand the application of artificial intelligence in the emerging field of drug discovery, and to choose to participate in the activities of interest nearby This guide includes 17 meetings according to the following criteria: 1 It must be highly active with a large number of speakers and participants; 2 It must include at least one group topic related to the application of drug discovery AI; 3 It must include speakers from related fields such as pharmaceutical companies (such as Johnson & Johnson, Merck), or technology companies (such as IBM, Microsoft) These companies are the main driving force for AI applications in drug discovery and the main end users of these technologies The selected conferences have the following common points: 1 They all include AI start-ups; 2 They all include highly respected scholars and scientists in the academic community, whose common point is to help AI experts develop efficient and practical technologies; 3 Most of the conferences are held in the United States or the United Kingdom, a few in Singapore and China Upcoming conference 1 The 2nd AI pharmaceutical innovation: drug discovery summit 2019 held in San Francisco on February 27 and 28 The conference will invite major decision makers from pharmaceutical companies, biotech drug developers and technology companies to discuss the application of data-driven artificial intelligence and machine learning in drug development, and share technical insights based on real world experience At this critical moment, it is expected to use artificial intelligence and machine learning technology to completely change the traditional pharmaceutical practice The purpose of this conference is to help participants find their own competitive advantages from this conference around solutions and fully tap the application potential of AI technology through the following ways: 1 Analyze the real world cases of Genentech, Berg, Amgen and other companies, and explore how to apply AI and machine learning methods in the field of pharmaceutical and Biotechnology; 2 Make clear how to build data sets optimally, so as to maximize the impact of AI and machine learning on the early drug development process; 3 Learn how to apply AI and machine learning to drug repositioning and reuse; 4 Discuss how to optimally integrate AI talents into the drug development process to simplify drug discovery; 5 Learn how machine learning can optimize molecular design to quickly track candidate drugs and make predictions 2 Phar East Venue: Singapore time: March 18-20 after its debut in 2018, phar East will again bring together experts from Asian Pharmaceutical and biotechnology companies, large pharmaceutical companies, regulatory agencies, uniform rooms, technology innovators and other aspects to share their professional knowledge and plan the way forward for Asian biomedicine The two-day conference will explore the four most exciting areas in the pharmaceutical industry in Asia: 1 Immunotherapy 2 Market access 3 Regulatory affairs 4 Pharmaceutical 4.0 phar East is the preferred meeting place for senior managers in the pharmaceutical and biotechnology industries in Asia 3 Healthcare & Medical Research Conference in the United States March 18-22 The conference on health care and medical research is part of NVIDIA's GPU Technology Conference (GTC), the leading artificial intelligence and deep learning conference, providing training, insights and direct contact with advanced life sciences, pharmaceutical and biomedical research experts, or experts in AI and deep learning, Internet of things, and autopilot Attendees can choose from more than 500 meetings and courses, and build extensive relationships with technology leaders in various fields To explore how GPU driven AI can realize personalized medical treatment, improve population health management and improve patient treatment effect In depth study of the latest AI progress in genomics, medical imaging and drug discovery (specific topics are not announced yet) 4 The 2019 global AI empowered healthcare China Summit 2019 is held in Shanghai, China on March 28 The 2019 global AI assisted healthcare China Summit will be held in Shanghai on March 28, 2019 The event will attract 800 business leaders from more than 30 countries around the world, who are from top international medical and life science CTOs/ CIO and it expert groups, high-tech giants, medical research institutions and laboratories, medical AI solution providers, pharmaceutical companies, medical equipment companies, medical software companies and large hospitals In this event, the sponsor will arrange one-to-one project matching for the sponsors, and provide opportunities for each major player in the medical AI industry chain to show their brands and cooperate with medical institutions At the same time, the event will also hold small exhibitions and industry award ceremony Through this event, participants can have a deeper understanding of global medical AI technology innovation and market trends, obtain relevant domestic and foreign policies and industry information, take advantage of the business opportunities brought by AI + health care potential, seize the opportunity, and lead the market peers in the coming vigorous development! (specific topics are not announced yet) 5 Venue of the 11th dia China annual meeting 2019: Beijing, China time: May 20-23, may of each year, China International Drug Information Conference and dia focusing on regulatory science and clinical The annual conference of China (hereinafter referred to as the "Annual Conference") has become an opportunity to exchange academic and practical knowledge, expand professional networks, and display professional services In the upcoming 2019 China International Drug Information Conference and the 11th dia China Annual Conference on May 20-23, 2019, we will focus on China's drug safety and quality with drug regulatory science as the core This annual meeting plans to set up more than 80 sub venues with 14 topics in the fields of regulatory science, implementation and new progress of ICH guidelines, clinical operation and quality compliance, clinical safety and pharmacovigilance, data standards, etc., to help consolidate the foundation of new drug research and development, promote high-quality new drug development, and effectively meet the needs of patients (specific topics are not announced yet) 6 Venue of the deep learning in healthcare Summit: Boston, USA on May 23 and 24 The health care deep learning summit will return to Boston on the east coast to hold an annual conference, bringing together the opinions of medical industry leaders, scholars, researchers and innovative start-ups to promote deep learning technology and apply it to the health field Focusing on medical imaging, diagnosis, personalized medicine and how to apply deep learning in medicine, patient care, health and well-being, this summit is an excellent way to discover the latest insights, assess the status of the industry and understand how deep learning affects the work of participants, and provide opportunities to connect with other important members of the community (specific topics are not announced yet) 7 Amlai for drug discovery and development Venue: London, UK time: May 28 and 29 this is a small forum, which is expected to have nearly 80 participants, including 20 speakers, and a total of 25 interactive meetings will be held Leading experts in AI and machine learning will be invited to discuss how to solve the obstacles of pharmaceutical innovation Participants are carefully selected senior managers, experts and business professionals, who will exchange experiences and share knowledge in the form of group discussions, real world research, interactive exchanges and seminars during the two-day meeting Overview of topics: 1 Unleashing the potential of machine learning for drug discovery and development 2 Indicating opportunities for expansion and drug targeting - Transforming Science 3 Are pharmaceutical companies ready to adopt these technologies and change healthcare? 4 From finance to AI drug discovery: the implementation of modern portfolio theory (MPT) of drug pipeline 5 How can leaders use big data analysis to achieve better and faster customer decision-making? 6 Use advanced analysis in goal selection and verification 7 Use AI / machine learning to strengthen customer-centered 8 Location of AI innovations for life science summit West: June 13, 14, USA This activity will bring together AI thought leaders in the field of life sciences, discuss how the industry can transform rapidly to make better use of existing technologies, and further discuss how AI is currently applied to: 1 Identify novel indications of compounds with large libraries; 2 Predict the efficacy of potential new drugs before clinical trials; 3 Identify a variety of compounds that may be combined to treat new indications or improve efficacy; 4 Reduce medical diagnosis errors in oncology and pathology; 5 Understand how to use a digital treatment platform to locate multiple indications; 6 Understand in-depth implementation issues related to learning systems in clinical development; 7 Improve treatment compliance and patient recruitment efficiency in clinical trial design; 8 Check data management system to understand privacy, protection and data ownership management; 9 Implement cutting-edge health data strategy while maintaining compliance within a complex privacy and regulatory framework; 10 Outline the AI that may be encountered in the current drug discovery process